Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Reducing carbon impact of inhalers
Find out about the carbon impact of different inhaler types and more about the Ellipta device on our device & dosing page.
A cost-effective single inhaler triple therapy for COPD¹ ²
At £44.50 Trelegy Ellipta costs less than commonly prescribed multiple inhaler triple therapies in the UK¹ ²
Cost of Trelegy Ellipta compared to other branded multiple inhaler triple therapy combinations in COPD:
*Spiriva HandiHaler; NB: All doses stated are delivered doses. BUD, budesonide; FOR, formoterol; FP, fluticasone propionate; mcg, microgram; MITT, multiple inhaler triple therapies; SAL, salmeterol; SITT, single inhaler triple therapy TIO, tiotropium; FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol
SERETIDE (Salmeterol xinafoate/fluticasone propionate) Prescribing Information
Get started with Trelegy Ellipta
Footnotes
Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β₂-agonist or a combination of a long-acting β₂-agonist and a long-acting muscarinic antagonist.⁶
Trelegy Ellipta is generally well tolerated. Common adverse reactions include: headache, nasopharyngitis, influenza, upper respiratory tract infection, pneumonia, back pain, rhinitis, cough, pharyngitis, arthralgia, sinusitis, oropharyngeal pain, bronchitis, constipation, candidiasis of mouth and throat, urinary tract infection.⁶
In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta.⁶
References
- MIMS Available at: https://www.mims.co.uk/. (Accessed Jan 2020)
- GSK Data on file: Combined Triple Therapy Combinations for COPD UK/TLY/0089/18 (REF-3515)
- Svedsater H et al BMC Pulm Med 2013; 13:1–14.
- van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
- Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873–1880.
- Trelegy Ellipta SmPC
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with
PM-GB-FVU-WCNT-200006 | July 2020
